A Study to Evaluate 20vPnC in Healthy Chinese Infants
← catalyst calendarNCT07754539 · readout in 834 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Triple · Prevention
Enrollment
1,250estimated
Sites
4
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-07-25 | actual | When the study began enrolling |
| Primary completion | 2028-11-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2031-05-31 | estimated | The whole study's end, after follow-up |
| First posted | 2026-08-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Pneumococcal Diseases
Interventions
- Biological: 20vPnC
- Biological: 13vPnC
Primary outcomes
what the primary-completion date above is the date OFPercentage of participants reporting prespecified local reactions
measured From Day 1 (the day of vaccination) through Day 7 following Vaccinations 1, 2, 3, and 4
Percentage of participants reporting prespecified systemic events
measured From Day 1 (the day of vaccination) through Day 7 following Vaccinations 1, 2, 3, and 4
Percentage of participants reporting Adverse Events (AEs) from the first study vaccination through 1 month following the third study vaccination.
measured From the first study vaccination to 1 month after the third study vaccination
Percentage of participants reporting AEs from the fourth study vaccination to 1 month following the fourth study vaccination.
measured From the fourth study vaccination to 1 month after the fourth study vaccination
Percentage of participants reporting serious adverse events (SAEs) through 6 months post last vaccination
measured From the first study vaccination to 6 months after the last study vaccination
The percentages of participants with predefined serotype-specific immunoglobulin G (IgG) concentrations in 20vPnC group compared to 13vPnC group at 1 month after Dose 3
measured At 1 month after Dose 3
The serotype-specific IgG geometric mean concentrations (GMCs) in 20vPnC group compared to 13vPnC group at 1 month after Dose 3
measured At 1 month after Dose 3
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed